The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Quality of life (QOL) evaluation within a randomized phase III study of gemcitabine plus S-1 (GS) versus S-1 versus gemcitabine (GEM) in unresectable, advanced pancreatic cancer (PC) in Japan and Taiwan: GEST study.
Y. Ohashi
Consultant or Advisory Role - Taiho Pharmaceutical
Honoraria - Taiho Pharmaceutical
M. Tanaka
Consultant or Advisory Role - Taiho Pharmaceutical
Honoraria - Taiho Pharmaceutical
Research Funding - Taiho Pharmaceutical
N. Boku
Consultant or Advisory Role - Taiho Pharmaceutical
Research Funding - Taiho Pharmaceutical
H. Ueno
Consultant or Advisory Role - Taiho Pharmaceutical
Honoraria - Lilly; Taiho Pharmaceutical
T. Okusaka
Consultant or Advisory Role - Taiho Pharmaceutical
Honoraria - Lilly; Taiho Pharmaceutical
Research Funding - Lilly; Taiho Pharmaceutical